NCT07108504View on ClinicalTrials.gov

Efficacy and Safety of LM-302 Combined With Gemcitabine CLDN 18.2 Positive Unresectable Locally Advanced or Metastatic Pancreatic Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

August 10, 2025

Primary Completion Date

August 10, 2026

Study Completion Date

August 10, 2028

Conditions

Pancreatic CancerChemotherapy Effect

Interventions

DRUG

Gemcitabine

Gemcitabine, 1000 mg/m², d1, 8, 15, q4 week

DRUG

LM-302

LM-302, 1.8 mg/kg, d1, q2 week

All Listed Sponsors

lead

Shanghai Zhongshan Hospital

OTHER